BRAF and thyroid gland carcinoma: By using a combination of genetic and pharmacological approaches, we found that pSMAD activation is increased in BRAF-mutant thyroid cancers, and that this is due to promiscuous engagement of activin and TGFβ family ligands with their corresponding receptors.